Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T73223 | NS5A-IN-3 | HCV Protease | Microbiology/Virology; Proteases/Proteasome |
NS5A-IN-3 (Compound 15) 为高效NS5A抑制剂,对HCV基因型1b显示出高效力,并对基因型3a (GT 3a) 活性提升以及展现出良好的代谢稳定性。NS5A-IN-3相较于daclatasvir,对基因型1b具有更高的耐药门槛。 | |||
T6229 |
Daclatasvir
Daklinza,达卡他韦,EBP 883,达拉他韦,BMS-790052 |
HCV Protease | Microbiology/Virology; Proteases/Proteasome |
Daclatasvir (EBP 883) 是一种高度选择性的 HCV NS5A 抑制剂,EC50 为 9-50 pM,适用于细胞培养中的多种 HCV 复制子基因型和 JFH-1 基因型 2a 感染性病毒。 | |||
T11548 |
HCV-IN-7
|
Others | Others |
HCV-IN-7 is an orally active and potent pan-genotypic HCV NS5A inhibitor (IC50s: 3-47 pM). It shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. | |||
T11548L |
HCV-IN-7 hydrochloride
|
Others | Others |
HCV-IN-7 hydrochloride is an orally active and potent pan-genotypic HCV NS5A inhibitor (IC50s: 3-47 pM). It shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. | |||
TP1468 |
HCV-IN-4
|
||
HCV-IN-4, a potent and orally active inhibitor of HCV NS5A, demonstrates significant efficacy against genotypes GT1a, GT2b, GT3a, and the GT1a mutations Y93H and L31V. Its half-maximal effective concentrations (EC90s) are 3 pM, 0.3 nM, 0.01 nM, 0.5 nM, and 0.02 nM, respectively[1]. |